Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,341.60
(
-1.56%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
106.16
(
1.90%
)
Bitcoin
80,521.92
(
-0.66%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 100097

Thursday, 08/26/2010 6:41:05 AM

Thursday, August 26, 2010 6:41:05 AM

Post# of 257566
SNY reiterates no plan for Lovenox authorized generic; this is implicit in the following excerpt from today’s PR:

http://en.sanofi-aventis.com/binaries/20100826_lovenox_en_tcm28-29053.pdf

Pending a final decision on the merits of the underlying complaint, sanofi-aventis will continue to make original enoxaparin (Lovenox®) available to healthcare professionals for their patients.

The word original is the key.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today